Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 181Lymphoma 97Lymphoma, Large B-Cell, Diffuse 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 79Sarcoma 69Hodgkin Disease 54Lymphoma, Non-Hodgkin 41Triple Negative Breast Neoplasms 37Burkitt Lymphoma 36Lymphoma, Mantle-Cell 32Leukemia 32Lymphoma, Follicular 30Multiple Myeloma 28Carcinoma, Hepatocellular 28Neoplasm Metastasis 23Ovarian Neoplasms 21Neoplasms 21Lymphoma, Large-Cell, Anaplastic 18Osteosarcoma 17Lymphoma, B-Cell 17Prostatic Neoplasms 16Neuroblastoma 15Lymphoma, T-Cell, Peripheral 15Urinary Bladder Neoplasms 14Recurrence 13Lymphoma, Large-Cell, Immunoblastic 13Inflammatory Breast Neoplasms 13Immunoblastic Lymphadenopathy 13Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Stomach Neoplasms 10

Interventions

Fluorodeoxyglucose F18 7Irinotecan 4Fluorouracil 4Cyclophosphamide 4Bevacizumab 4toripalimab 3pembrolizumab 3olaparib 3Radiosurgery 3Cisplatin 3Capecitabine 3vistusertib 2tislelizumab 2spartalizumab 2fludarabine 2atezolizumab 2apatinib 2Temozolomide 2Technetium 2Specimen Handling 2Sirolimus 2Radiotherapy 2Proton Therapy 2Paclitaxel 2Leucovorin 2Letrozole 2Hydroxychloroquine 2Everolimus 2Drug Therapy 2Docetaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Solid Tumor × Doxorubicin × Clear all
NCT05661201 2026-03-06

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

Georgetown University

Phase 1 Recruiting
24 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡